Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tessa Hedley-Whyte, M.D., M.B.,B.S.

Co-Author

This page shows the publications co-authored by Tessa Hedley-Whyte and Anne Klibanski.
Connection Strength

0.735
  1. Tritos NA, Eppakayala S, Swearingen B, Hedley-Whyte ET, Miller KK, Nachtigall LB, Grinspoon SK, Biller BM, Klibanski A. Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity. Pituitary. 2013 Sep; 16(3):287-93.
    View in: PubMed
    Score: 0.155
  2. Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, Stratakis CA, Hedley-Whyte ET, Klibanski A. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 2008 Oct; 93(10):4119-25.
    View in: PubMed
    Score: 0.108
  3. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006 Nov; 91(11):4482-8.
    View in: PubMed
    Score: 0.095
  4. Danila DC, Inder WJ, Zhang X, Alexander JM, Swearingen B, Hedley-Whyte ET, Klibanski A. Activin effects on neoplastic proliferation of human pituitary tumors. J Clin Endocrinol Metab. 2000 Mar; 85(3):1009-15.
    View in: PubMed
    Score: 0.061
  5. Danila DC, Zhang X, Zhou Y, Dickersin GR, Fletcher JA, Hedley-Whyte ET, Selig MK, Johnson SR, Klibanski A. A human pituitary tumor-derived folliculostellate cell line. J Clin Endocrinol Metab. 2000 Mar; 85(3):1180-7.
    View in: PubMed
    Score: 0.061
  6. Schorr M, Zhang X, Zhao W, Abedi P, Lines KE, Hedley-Whyte ET, Swearingen B, Klibanski A, Miller KK, Thakker RV, Nachtigall LB. TWO SYNCHRONOUS PITUITARY ADENOMAS CAUSING CUSHING DISEASE AND ACROMEGALY. AACE Clin Case Rep. 2019 Sep-Oct; 5(5):e276-e281.
    View in: PubMed
    Score: 0.058
  7. Katznelson L, Bogan JS, Trob JR, Schoenfeld DA, Hedley-Whyte ET, Hsu DW, Zervas NT, Swearingen B, Sleeper M, Klibanski A. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab. 1998 May; 83(5):1619-23.
    View in: PubMed
    Score: 0.053
  8. Cai WY, Alexander JM, Hedley-Whyte ET, Scheithauer BW, Jameson JL, Zervas NT, Klibanski A. ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab. 1994 Jan; 78(1):89-93.
    View in: PubMed
    Score: 0.040
  9. Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A, Hedley-Whyte ET. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg. 1993 May; 78(5):753-61.
    View in: PubMed
    Score: 0.038
  10. Biller BM, Alexander JM, Zervas NT, Hedley-Whyte ET, Arnold A, Klibanski A. Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab. 1992 Nov; 75(5):1303-9.
    View in: PubMed
    Score: 0.036
  11. Harris PE, Alexander JM, Bikkal HA, Hsu DW, Hedley-Whyte ET, Klibanski A, Jameson JL. Glycoprotein hormone alpha-subunit production in somatotroph adenomas with and without Gs alpha mutations. J Clin Endocrinol Metab. 1992 Sep; 75(3):918-23.
    View in: PubMed
    Score: 0.009
  12. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL. Ras mutations in human pituitary tumors. J Clin Endocrinol Metab. 1992 Apr; 74(4):914-9.
    View in: PubMed
    Score: 0.009
  13. el-Azouzi M, Hsu DW, Black PM, Jolesz F, Hedley-Whyte ET, Klibanski A, Zervas NT. The importance of dopamine in the pathogenesis of experimental prolactinomas. J Neurosurg. 1990 Feb; 72(2):273-81.
    View in: PubMed
    Score: 0.008
  14. Black PM, Hsu DW, Klibanski A, Kliman B, Jameson JL, Ridgway EC, Hedley-Whyte ET, Zervas NT. Hormone production in clinically nonfunctioning pituitary adenomas. J Neurosurg. 1987 Feb; 66(2):244-50.
    View in: PubMed
    Score: 0.006
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.